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Short-Term Serial Sampling of Natriuretic
Peptides in Patients Presenting With Chest Pain
Gene Kwan, MD,* Susan R. Isakson, BS,* Jennifer Beede, MS,* Paul Clopton, MS,*
Alan S. Maisel, MD, FACC,* Robert L. Fitzgerald, PHD†
San Diego, California
Objectives The purpose of this study was to characterize the diagnostic and prognostic utility of short-term dynamic
changes in natriuretic peptides in patients presenting with chest pain.
Background Although single levels of natriuretic peptides in patients admitted for acute coronary syndromes (ACS) have
important prognostic value, it is unclear whether serial sampling of natriuretic peptides might have both
diagnostic and prognostic value in the setting of chest pain.
Methods We followed 276 patients for 90 days who presented to the emergency department with chest pain. We sam-
pled brain natriuretic peptide (BNP) and amino-terminal (NT)-proBNP up to 5 times within 24 h of presentation
and again at discharge. Follow-up data was collected at 30 and 90 days after admission. Adverse events in-
cluded emergency department visits for chest pain, cardiac readmission, and death. We assessed the prognostic
and diagnostic value of baseline natriuretic peptide measurements with receiver-operating characteristic
analyses.
Results Natriuretic peptides were diagnostic for congestive heart failure (CHF) and new-onset CHF but less so for ACS.
The prognostic utility of serial sampling was evaluated through testing the statistical contribution of each future
time point (as well as variability over time) over and above the baseline values in logistic regression models.
Conclusions Baseline elevated BNP and NT-proBNP concentrations were predictive of adverse events at 30 and 90 days.
Serial sampling did not improve the prognostic value of BNP or NT-proBNP. (J Am Coll Cardiol 2007;49:
1186–92) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.11.031h
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wwenty percent of patients arriving at the emergency
epartment have symptoms suggestive of acute myocardial
nfarction (MI) (1). Diagnosis of acute MI is based on the
ise and fall of troponin or creatine kinase-MB with at least
of the following: ischemic symptoms, electrocardiographic
ECG) changes, or coronary artery intervention (2). Al-
hough the tissue specificity of cardiac troponin T (cTnT)
nd cardiac troponin I have improved our ability to make an
ccurate diagnosis, there is a continued search for optimal
arkers for acute coronary syndromes (ACS).
Natriuretic peptides, which have primarily been devoted
o the diagnosis of congestive heart failure (CHF) (3), have
lso been found to be elevated in the setting of ACS (1,3–5).
atriuretic peptides are vasoactive hormones secreted by the
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rticle.n
Manuscript received May 18, 2006; revised manuscript received October 31, 2006,
ccepted November 7, 2006.eart as part of a systemic response to cardiac stress and
entricular dysfunction. The precursor peptide of brain
atriuretic peptide (BNP) is stored in granules of ventricular
yocytes. There, it is cleaved into an amino-terminal
roduct (NT-proBNP) and the physiologically active BNP
6). Release of BNP and NT-proBNP are regulated by wall
tress and myocyte stretch (6–8). The BNP levels trend
pward to a peak between 14 and 40 h after an ischemic
vent (5–6,9). Elevated BNP and NT-proBNP concentra-
ions at admission in the setting of ACS are associated with
oor prognosis, including increased mortality, development
f CHF, and recurrent ischemic events (6,10–13).
The present study sought to characterize the diagnostic
nd prognostic utility of short-term dynamic changes in
NP and NT-proBNP in patients presenting to the emer-
ency department with chest pain. Most previous studies
nvolving the serial use of natriuretic peptides in the setting
f ACS examined time points in the time frame of days,
eeks, and months (5–8). Because BNP is synthesized on
emand in response to an appropriate stimulus (8), we
ere interested in determining if serial measurements of
atriuretic peptides during the first 24 h had diagnostic
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easurements.
ethods
atient enrollment. From July 2003 through April 2005,
06 patients presenting with chest pain to the emergency
epartment at the Veterans Affairs Medical Center, La
olla, California, were enrolled. The inclusion criteria were
ge 18 years, symptoms suggestive of cardiac ischemia,
nd ability to provide informed consent. The study was
pproved by the institutional review board. A sample size of
00 was determined to yield a power of 0.8 for an odds ratio
f 2.0. Of the 306 subjects who consented, patients with
nly 1 time point or with no baseline sample were excluded,
eaving a total of 276 patients included in the data analysis.
iomarker sampling. We sampled BNP and NT-proBNP
t up to 5 time points within the first 24 h of presentation
baseline, 90 min to 3 h, 3 to 6 h, 6 to 12 h, and 12 to 24 h)
nd again at discharge. Troponin T (TnT) was sampled at
to 6 h after presentation.
iomarker testing. All samples were collected in plastic
DTA tubes and frozen at70°C until the time of analysis.
he BNP testing was performed using both an Advia
entaur BNP assay (Bayer Healthcare, Tarrytown, New
ork) and Triage BNP assay (Biosite Diagnostics, San
iego, California). The NT-proBNP and TnT were mea-
ured with an Elecsys 2010 analyzer (Roche Diagnostics,
ndianapolis, Indiana). Clinicians could order BNP (Biosite
ssay), cardiac troponin I, myoglobin, and creatine
inase-MB tests for clinical purposes to aid in ACS diag-
osis. Cardiac biomarkers (research BNP, NT-proBNP,
nd cTnT) obtained solely for research purposes were not
ade available to clinicians.
ollow-up. Final diagnoses were assigned for all patients
y the same cardiologist based on patient history, biochem-
cal data, and diagnostic procedures. Acute coronary syn-
rome was defined as ST-segment elevation MI, non–ST-
egment elevation MI, or unstable angina (UA), Unstable
ngina was a clinical diagnosis based on ischemic chest pain
nd absence or presence of ECG changes without elevations
f cardiac markers. Unstable angina was confirmed by stress
esting or coronary angiography. Patients were followed for
0 days, and outcome data were collected after both 30 and
0 days by chart review. A combined end point included
epeat emergency department visits for chest pain, cardiac-
elated readmission, and death.
tatistical analyses. Patients with only 1 sample were
emoved from the data analysis. Means with standard
eviations or percentages were used for description of the
ample. Natriuretic peptide levels are presented as medians
or various patient groupings and compared with Mann-
hitney U tests. Receiver-operating characteristic (ROC)
urves were used to evaluate diagnostic and prognostic
tility. To assess the prognostic contribution of serial
atriuretic peptide measurements, logistic regression models fere used. Log-transformed na-
riuretic peptide values were used
hroughout. Prognostic utility
as evaluated in 2-step models in
hich the baseline value was en-
ered first, followed by a test of
he incremental contribution of
ither the 90-min value, the
tandard deviation of all values
to evaluate the variability over
ime), or the mean of all values.
dds ratios were not adjusted for
ther demographic or clinical in-
icators. Pearson correlation of
og-transformed values was used
o quantify the relationship of baseline levels to subsequent
evels. All data analysis was performed using SPSS version
3.0 (SPSS Inc., Chicago, Illinois).
esults
atient characteristics are shown in Table 1. Table 2 shows
he median natriuretic peptide concentrations at presenta-
ion for the various patient subgroups. Patients older than
5 years had significantly higher natriuretic peptide concen-
rations than younger patients. Reduced BNP and
T-proBNP levels were seen in obese patients (body mass
ndex30 kg/m2). As would be expected, a history of CHF
as associated with higher baseline natriuretic peptide
oncentrations. This was also true of patients with a prior
I and known coronary artery disease (CAD). These
rends were not seen among those with diabetes, hyperten-
ion, hyperlipidemia, smoking history, or a family history of
remature CAD. Stage 2 or worse chronic kidney disease
estimated glomerular filtration rate 90 ml/min) (14) was
ssociated with elevated natriuretic peptides. Positive TnT
evels (0.2 ng/ml between 3 and 6 h) were not associated
ith high baseline peptide levels.
The diagnostic utility of these natriuretic peptides was
rst evaluated through ROC analysis. When using baseline
atriuretic peptide levels, the ROCs for the diagnosis of
HF were highly significant. The area under the curve
AUC) (95% confidence interval [CI]) was 0.94 (95% CI
.91 to 0.98) for BNP (Bayer), 0.93 (95% CI 0.89 to 0.97)
or BNP (Biosite), and 0.92 (95% CI 0.87 to 0.96) for
T-proBNP. The ROC analysis also found baseline natri-
retic peptides to be useful in detecting new-onset CHF in
atients without a prior history of CHF: AUC 0.90 (95%
I 0.83 to 0.97) for BNP (Bayer), 0.85 (95% CI 0.77 to
.96) for BNP (Biosite), and 0.84 (95% 0.75 to 0.93) for
T-proBNP. When the same ROC analysis was applied to
CS diagnosis, the results were much more equivocal. The
UC was 0.58 (95% CI 0.51 to 0.65) for BNP (Bayer), 0.57
95% CI 0.50 to 0.65) for BNP (Biosite), and 0.56 (95% CI
.49 to 0.63) for NT-proBNP. Similar results were obtained
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
BNP  brain natriuretic
peptide
CI  confidence interval
MI  myocardial infarction
NT-proBNP  amino-
terminal pro-brain
natriuretic peptide
ROC  receiver-operating
characteristicor differentiating cardiac chest pain from noncardiac chest
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.65 (95% CI 0.58 to 0.72) for BNP (Biosite), and 0.64
95% CI 0.57 to 0.71) for NT-proBNP.
Baseline natriuretic peptide concentrations were consis-
ently associated with 30- and 90-day adverse events
Table 3). This composite outcome includes mortality,
resentation to the emergency department with a complaint
f chest pain, and cardiac-related readmission. The median
atriuretic peptide concentrations were significantly differ-
nt between those with and those without adverse events at
0 days (122 vs. 50 pg/ml [p  0.001] for Bayer BNP, 141
s. 57 pg/ml [p  0.001] for Biosite BNP, and 882 vs. 212
g/ml [p  0.001] for NT-proBNP). This held true at 90
ays as well (120 vs. 46 pg/ml [p  0.001] for Bayer BNP,
29 vs. 49 pg/ml [p  0.001] for Biosite BNP, and 819 vs.
90 pg/ml [p  0.001] for NT-proBNP). Table 4 shows
atient Characteristics (n  276)
Table 1 Patient Characteristics (n  276)
Demographics (%)
Age65 yrs 38.0
Gender (% male) 96.7
Race
White 79.0
Black 9.8
Hispanic 9.1
Asian 2.2
BMI30 kg/m2 43.4
History (%)
CHF 27.5
CAD 59.3
MI 49.6
PTCA 37.1
CABG 26.4
DM 44.7
HTN 74.6
Family history of CAD 60.5
Hyperlipidemia 66.9
Cigarette smoking 79.7
Lab values*
eGFR90 ml/min (%) 75.7
BNP (Bayer) pg/ml 57 (20–142)
BNP (Biosite) pg/ml 62 (18–163)
NT-proBNP pg/ml 249 (6–1,015)
cTnT0.20 ng/ml (%) 44.9
Number of patients at each time point
Admission 276
90 min to 3 h 215
3 h to 6 h 189
6 h to 12 h 187
12 h to 24 h 163
Discharge 132
Natriuretic peptide data are reported as median (25% percentile to 75% percentile).
BMI  body mass index; BNP  brain natriuretic peptide; CABG  coronary artery bypass graft;
AD  coronary artery disease; CHF  congestive heart failure; cTnT  cardiac troponin T; DM 
iabetes mellitus; eGFR  estimated glomerular filtration rate; HTN  hypertension; MI 
yocardial infarction; NT-proBNP  amino-terminal pro-brain natriuretic peptide; PTCA  percu-
aneous transluminal coronary angiography.hat natriuretic peptides were able to predict the separate and points of readmission for cardiac-related reasons and
eath but not emergency department visits.
Receiver-operating characteristics showed that baseline
NP and NT-proBNP measurements are predictive of 30-
nd 90-day adverse events (Fig. 1). For baseline natriuretic
eptides, the AUC for 30-day adverse events was 0.685
95% CI 0.587 to 0.783) for Bayer BNP, 0.678 (95% CI
.587 to 0.782) for Biosite BNP, and 0.707 (95% CI 0.617
o 0.798) for NT-proBNP. The results were similar for
0-day adverse events: 0.663 (95% CI 0.584 to 0.742) for
ayer BNP, 0.678 (95% CI 0.598 to 0.758) for Biosite
NP, and 0.694 (95% CI 0.621 to 0.767) for NT-proBNP.
hese curves were used to determine cut points for the 2
eptides to evaluate the likelihood of adverse events. Deci-
ion limits yielding 70% sensitivity for the Bayer BNP assay
re 52 pg/ml (50.4% specificity) for 30-day events and 46
g/ml (50.0% specificity) for 90-day events. Cut points for
0% sensitivity for the other 2 assays are 59 pg/ml for
iosite BNP (specificity of 51.4% and 53.6% at 30 and 90
ays, respectively) and 222 pg/ml for NT-proBNP (speci-
city of 51.5% and 54.1% at 30 and 90 days, respectively).
To assess the prognostic contribution of subsequent
atriuretic peptide measurements in addition to baseline
evels, logistic regression models were used (Table 5) with
og-transformed concentrations used throughout. The base-
ine levels of natriuretic peptides were significant predictors
f 30- and 90-day events (p  0.001 in all cases). The
0-min observations did not add significant additional
rognostic utility to the baseline model (p  0.329 to
.855). To explore whether or not individual variability
nondirectional) was prognostic beyond baseline values the
tandard deviation of values was used. The variability of
atriuretic peptides did not add significant additional prog-
ostic utility to the baseline model (p  0.251 to 0.962).
inally, the average of all time points did not add additional
rognostic utility (p  0.152 to 0.908). Cardiac TnT
levation of 0.2 pg/ml at 3 to 6 h was also unable to add
o the prognostic utility of baseline natriuretic peptides (data
ot shown). We also examined lower concentrations of
TnT, and they did not add prognostic value.
Correlations of natriuretic peptide levels at baseline with
ubsequent time points are presented in Table 6. The
aseline levels correlated highly with subsequent samples
aken up to 12 h after presentation (all correlations 0.91).
his indicates that measurements taken at baseline were
ery predictive of subsequent concentrations.
iscussion
he roles of BNP and NT-proBNP are well established for
eart failure. However, their utility in ACS is still evolving.
lthough diagnostic, prognostic and treatment strategies
or ST-segment elevation MI have become routine, given
he universal use of thrombolysis and early-invasive reper-
usion, the same is not true of non–ST-segment elevation
cute coronary syndrome (NSTEACS). Patients with
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tratification increasingly important. The present study
ocused on the assessment of neurohormonal activation to
id in diagnosis and prognosis of these groups.
Brain natriuretic peptide has been found to increase in
he setting of MI. Peak levels occur 14 to 40 h after the
schemic event (5–6). The degree of natriuretic peptide
levation is related to the size of the ischemic injury
15–16). The amount of compensatory force generated by
he remaining functional myocardium must increase for the
eart to generate adequate forward flow. This increased
orce could result in increased natriuretic peptide expression
nd secretion.
Unlike BNP, the kinetics of NT-proBNP is governed
rimarily by renal excretion (17). In addition to renal
xcretion, BNP is actively degraded by circulating endo-
eptidases as well as cleared by cellular binding receptors
18). This results in a longer half-life for NT-proBNP (70
o 120 min) than BNP (20 min) (17–19). The longer
alf-life may allow for greater accumulation of NT-proBNP
nd potentially greater sensitivity in detecting more subtle
tructural and functional changes. A greater incremental rise
n NT-proBNP has been noted in patients with cardiac
oncentration of Natriuretic Peptides at Presentation (Medians in
Table 2 Concentration of Natriuretic Peptides at Presentation
BNP (Bayer)
Characteristic Yes No p Value
Demographics
Age65 yrs 114 33 0.001
Gender (male) 57 61 0.912
BMI30 kg/m2 46 65 0.046
History
CHF 156 39 0.001
CAD 69 33 0.005
MI 78 42 0.001
PTCA 69 52 0.091
CABG 73 46 0.027
DM 72 47 0.188
HTN 68 37 0.055
Family history of CAD 67 48 0.258
Hyperlipidemia 56 63 0.621
Smoker 59 45 0.835
Lab values
eGFR90 ml/min 65 38 0.020
CTnT0.20 ng/ml* 67 61 0.672
cTnT as measured between 3 and 6 h after presentation.
Abbreviations as in Table 1.
Concentration of Natriuretic Peptides(Medians in pg/ml) at Presentation for End Poin
Table 3 Concentration of Natriuretic Peptid(Medians in pg/ml) at Presentation
BNP (Bayer)
Prognosis Yes No p Value
30-day adverse event 122 50 0.001
90-day adverse event 120 46 0.001Abbreviations as in Table 1.ecompensation (17). However, the greater half-life of
T-proBNP may result in a masking of subtle acute
hanges in cardiac function. Also, in patients with renal
nsufficiency, NT-proBNP may accumulate relative to BNP
nd potentially overshadow clinically significant changes.
In this study, several trends were observed relating to the
ehavior of natriuretic peptide concentrations in the pres-
nce of comorbid conditions. Higher natriuretic peptide
oncentrations levels were associated with low estimated
lomerular filtration rates. Impaired renal function often
eads to elevated natriuretic peptide levels because of de-
reased clearance rates (20). Obese patients were found to
ave lower natriuretic peptide concentrations levels than
onobese patients. This is in part a result of increased
atriuretic peptide receptor-containing adipose cells leading
o more rapid degradation of BNP (21,22). A recent study
uggests that obese patients also tend to have suppressed
atriuretic peptide secretion (23). This finding would ex-
lain lower NT-proBNP concentrations in obese patients.
In another study, elevated BNP of 100 pg/ml was
ound to be 70% sensitive for acute MI in patients with
STEACS, and an elevated troponin I was 51% sensitive
24). In the present population, we found that baseline
l) for Various Patient Groups
ians in pg/ml) for Various Patient Groups
BNP (Biosite) NT-proBNP (Roche)
No p Value Yes No p Value
35 0.001 733 156 0.001
61 0.994 247 293 0.890
66 0.035 215 341 0.043
41 0.001 1,121 163 0.001
39 0.023 374 184 0.035
44 0.002 433 174 0.002
61 0.177 342 220 0.246
54 0.026 462 213 0.050
57 0.302 310 212 0.265
47 0.086 289 213 0.064
56 0.199 247 222 0.293
80 0.528 215 367 0.178
59 0.699 244 283 0.604
44 0.067 320 174 0.006
62 0.800 284 293 0.942
ups
nd Point Groups
BNP (Biosite) NT-proBNP (Roche)
No p Value Yes No p Value
57 0.001 882 212 0.001
49 0.001 819 190 0.001pg/m
(Med
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150
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Short-Term Serial Changes of Natriuretic Peptides March 20, 2007:1186–92atriuretic peptide assessment was not a helpful clinical test
hen assessing for ACS diagnosis. Diagnostic power was
ot added to this test through short-term serial sampling.
owever, the natriuretic peptides clearly showed value in
etecting previously undiagnosed CHF in patients present-
ng with symptoms of ACS.
Natriuretic peptides assessed at baseline contribute to the
ultimarker approach to risk stratification in patients with
STEACS (25). Although the prognostic utility of baseline
NP and NT-proBNP has been established, questions
egarding the frequency of sampling have been only partially
nswered. A purpose of the present study was to evaluate the
elationship between short-term dynamic changes in natri-
retic peptide concentrations and prognosis. We show that
aseline assessment of natriuretic peptides is sufficient for
iagnosis of CHF, even in patients with no history of
ymptomatic ventricular dysfunction, and that these pep-
ides can be used to prognosticate poor outcomes. The
resent results show that serial sampling did not add
rognostic power to these biomarkers in the setting of ACS,
result that is similar to findings for CHF diagnosis (26).
hese results are consistent with an earlier report where
T-proBNP was sampled at baseline and 6 hours in ACS
atients, which concluded that the “incremental value of
erial measurements is limited” (27). Because we had a
imited number of samples after the 12-h time point, our
tudy does not rule out the value of serial sampling beyond
2 h. Our short-term serial sampling results are clearly
ifferent than those reported for longer-term follow-up of
CS patients in the outpatient setting. Morrow et al. (13)
emonstrated that serial sampling of BNP 4 and 12 months
fter presenting with symptoms of ACS predicted risk of
eath or new-onset CHF.
Analysis of the sensitivity and specificity of using natri-
retic peptides to predict future events was accomplished by
valuating ROCs. The admission BNP and NT-proBNP
ere found to be useful for assessing prognosis characterized
s adverse events at 30 and 90 days. Whereas there were
light differences in the AUC for the different BNP assays,
he 95% CIs overlapped, indicating that they are equally
seful. In this population, consisting of patients presenting
o the emergency department with symptoms of chest pain,
BNP concentration between 46 and 59 pg/ml was 70%
dds Ratios (95% Confidence Interval) of Logransformed Baseline Natriuretic Peptide Values forogn sis of Individual End Poi s at 90 Days
Table 4
Odds Ratios (95% Confidence Interval) of Log
Transformed Baseline Natriuretic Peptide Values for
Prognosis of Individual End Points at 90 Days
Assay
Visit to ED
(n  32)
Readmission
(n  22)
Death
(n  9)
BNP (Bayer) 1.6 (0.9–3.0) 2.3 (1.1–4.9) 7.9 (2.1–30)
BNP (Biosite) 1.4 (0.8–2.4) 2.7 (1.3–5.6) 11.7 (3.1–44)
NT-proBNP 1.5 (0.9–2.3) 2.3 (1.3–4.2) 6.8 (2.4–20)
isits to the emergency department (ED) were for complaints of chest pain. Readmissions were for
ardiac-related reasons.
Abbreviations as in Table 1.ensitive for predicting adverse events. For NT-proBNP, aoncentration of 222 pg/ml was 70% sensitive for predicting
dverse events. It is to be expected that a natriuretic peptide
evels in the diagnostic range for cardiac pathology would be
ssociated with increased adverse events. However, it was
urprising to find that such low decision thresholds for BNP
ould have such prognostic value.
Correlation analysis showed that the levels at baseline
ere providing essentially the same information as subse-
Figure 1 ROC Curves for Predicting Outcome in ACS
Patients From Baseline Natriuretic Peptide Levels
Combined outcomes tested at 30 (A) and 90 days (B). ACS  acute coronary
syndromes; AUC  area under the curve; BNP  brain natriuretic peptide; CI 
confidence interval; NT-proBNP  amino-terminal pro-brain natriuretic peptide;
ROC  receiver-operating characteristic.
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March 20, 2007:1186–92 Short-Term Serial Changes of Natriuretic Peptidesuent time points. With correlation coefficients between
aseline and 90-min data as high as 0.986, there is no
pportunity for the second observation to add prognostic
tility. The analytic precision of these assays in our labora-
ory is in the range of 2% to 12% (data not shown). The
btained correlation coefficients are so high as to suggest
hat the observed changes in levels could be explained by
ormal laboratory variation. The correlation between base-
ine and discharge values was the lowest observed. However,
ogistic regression for these discharge time points failed to
dd to the prediction of outcome, and therefore serial
onitoring within 24 h was not useful.
tudy limitations. Collecting a full set of serial data was
ifficult. Our protocol called for sampling of 6 time points
ver the course of hospitalization. Five samples were re-
uired within the first 24 h after admission. Because of this
ifficulty, a substantial number of patients were without
omplete data sets. All patients without baseline data or
ith only one data point were excluded from statistical
nalysis. Only 62 patients had complete sets of data with 6
lood samples. When presenting with chest pain and an
cute coronary syndrome is suspected, patients are immedi-
tely risk stratified in the emergency room. If a patient’s
linical history and electrocardiograms are not worrisome,
nd biomarkers sampled twice in the first 90 min are
egative, cardiac ischemia is generally ruled out. This
esulted in 36 patients with only 2 data points (admission
nd 90 min). Because the number of samples varied across
atients, we elected not to use peak or nadir natriuretic
eptide measures as predictors, because these indicators can
e confounded with the number of samples obtained.
Clinicians were allowed to order BNP for clinical uses.
his was done mostly on presentation but occasionally
fterward as well. This could lead to a bias in diagnosis
avoring CHF (and away from ACS) in those with
levated BNP. Although this is a valid criticism of the
resent study, it is not ethical to restrict measurement of
NP in patients presenting with symptoms of ACS.
atients who had elevated concentrations of BNP would
esult in more intensive therapy, presumably manifesting
s improved outcomes.
A final limitation of the study was that it was performed
orrelations of Baseline Natriureticeptide Levels With Subsequent Time Points
Table 6 Correlations of Baseline NatriureticPeptide Levels With Subsequent Time Points
Time Point
BNP
(Bayer)
BNP
(Biosite)
NT-proBNP
(Roche)
90 min to 3 h 0.971* 0.978* 0.986*
3 to 6 h 0.963* 0.968* 0.968*
6 to 12 h 0.913* 0.930* 0.935*
12 to 24 h 0.848* 0.881* 0.896*
Discharge 0.660* 0.695* 0.741*
p 0.01.
Abbreviations as in Table 1.in a Veterans Affairs Medical Center and therefore did notSu
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epresentative of other patient populations.
onclusions
he natriuretic peptides BNP and NT-proBNP provide a
easurement of ventricular dysfunction. Concentrations of
hese peptides rise in the setting of ischemia. Acute eleva-
ions detected on presentation with symptoms of ACS are
iagnostic for the development of CHF, even in patients
ithout a prior history of CHF. In this relatively small
ingle-site study, the prognostic value of natriuretic peptides
as in the assessment of baseline concentrations, and not in
hort-term monitoring for changing levels.
eprint requests and correspondence: Dr. Robert L. Fitzgerald,
AMC-113, 3350 La Jolla Village Drive, San Diego, California
2161. E-mail: rlfitzgerald@vapop.ucsd.edu.
EFERENCES
1. Karlson BW, Herlitz J, Pettersson P, Ekvall HE, Hjalmarsson A.
Patients admitted to the emergency room with symptoms indicative of
acute myocardial infarction. J Intern Med 1991;230:251–8.
2. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction
redefined—a consensus document of the Joint European Society of
Cardiology/American College of Cardiology Committee for the Re-
definition of Myocardial Infarction. J Am Coll Cardiol 2000;36:
959–69.
3. McCullough PA, Nowak RM, McCord J, et al. B-Type natriuretic
peptide and clinical judgment in emergency diagnosis of heart failure:
analysis from Breathing Not Properly (BNP) multinational study.
Circulation 2002;106:416–22.
4. Marumoto K, Hamada M, Aburaya M, Hiwada K. Augmented
secretion of atrial and brain natriuretic peptides during dynamic
exercise in patients with old myocardial infarction. Jpn Circ J 1995;
59:715–24.
5. Talwar S, Squire IB, Downie PF, et al. Profile of plasma N-terminal
proBNP following acute myocardial infarction; correlation with left
ventricular systolic dysfunction. Eur Heart J 2000;21:1514–21.
6. Morita E, Yasue H, Yoshimura M, et al. Increased plasma levels of
brain natriuretic peptide in patients with acute myocardial infarction.
Circulation 1993;88:82–91.
7. Motwani JG, McAlpine H, Kennedy N, Struthers AD. Plasma brain
natriuretic peptide as an indicator for angiotensin-converting-enzyme
inhibition after myocardial infarction. Lancet 1993;341:1109–13.
8. Hama N, Itoh H, Shirakami G, et al. Rapid ventricular induction of
brain natriuretic peptide gene expression in experimental acute myo-
cardial infarction. Circulation 1995;92:1558–64.9. Wiese S, Breyer T, Dragu A, et al. Gene expression of brain natriuretic
peptide in isolated atrial and ventricular human myocardium: influenceof angiotensin II and diastolic fiber length. Circulation 2000;102:
3074–9.
0. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur
J Heart Fail 2004;6:257–60.
1. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of
B-type natriuretic peptide in patients with acute coronary syndromes.
N Engl J Med 2001;345:1014–21.
2. Heeschen C, Hamm CW, Mitrovic V, et al. N-Terminal pro–B-type
natriuretic peptide levels for dynamic risk stratification of patients with
acute coronary syndromes. Circulation 2004;110:3206–12.
3. Morrow DA, de Lemos JA, Blazing MA, et al. Prognostic value of
serial B-type natriuretic peptide testing during follow-up of patients
with unstable coronary artery disease. JAMA 2005;294:2866–71.
4. National Kidney Foundation. K/DOQI clinical practice guidelines for
chronic kidney disease: evaluation, classification, and stratification.
Am J Kidney Dis 2002;39:S1–246.
5. Sabatine MS, Morrow DA, de Lemos JA, et al. Acute changes in
circulating natriuretic peptide levels in relation to myocardial ischemia.
J Am Coll Cardiol 2004;44:1988–95.
6. Jernberg T, James S, Lindahl B, et al. Natriuretic peptides in unstable
coronary artery disease. Eur Heart J 2004;25:1486–93.
7. Hunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive amino-
terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker
of cardiac impairment. Clin Endocrinol (Oxf) 1997;47:287–96.
8. Yoshimura M, Yasue H, Okumura K, et al. Different secretion
patterns of atrial natriuretic peptide and brain natriuretic peptide in
patients with congestive heart failure. Circulation 1993;87:464–9.
9. Pemberton CJ, Johnson ML, Yandle TG, et al. Deconvolution
analysis of cardiac natriuretic peptides during acute volume overload.
Hypertension 2000;36:355–9.
0. Haug C, Metzele A, Steffgen J, et al. Increased brain natriuretic
peptide and atrial natriuretic peptide plasma concentrations in dialysis-
dependent chronic renal failure and in patients with elevated left
ventricular filling pressure. Clin Invest 1994;72:430–4.
1. Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type
natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004;43:1590–5.
2. McCord J, Mundy BJ, Hudson MP, et al. Relationship between obesity and
B-type natriuretic peptide levels. Arch Intern Med 2004;164:2247–52.
3. Krauser DG, Lloyd-Jones DM, Chae CU, et al. Effect of body mass
index on natriuretic peptide levels in patients with acute congestive
heart failure: a ProBNP Investigation of Dyspnea in the Emergency
Department (PRIDE) substudy. Am Heart J 2005;149:744–50.
4. Bassan R, Potsch A, Maisel A, et al. B-type natriuretic peptide: a novel
early blood marker of acute myocardial infarction in patients with chest
pain and no ST-segment elevation. Eur Heart J 2005;26:234–40.
5. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach
to risk stratification in nonST elevation acute coronary syndromes:
simultaneous assessment of troponin I, C-reactive protein, and B-type
natriuretic peptide. Circulation 2002;105:1760–3.
6. Wu AH, Smith A, Apple FS. Optimum blood collection intervals for
B-type natriuretic peptide testing in patients with heart failure. Am J
Cardiol 2004;93:1562–3.
7. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-Terminal pro brain
natriuretic peptide on admission for early risk stratification of patients
with chest pain and no ST-segment elevation. J Am Coll Card
2002;40:437–45.
